Molecular Partners announced the MP0730 nomination on October 22, selecting the CD70-targeting candidate as its third targeted alpha radiotherapy program. The decision follows preclinical findings in tumor-bearing mice that the company said showed sustained tumor uptake relative to healthy tissues. A first-in-human program is expected in 2027, although the announcement gives differing timing references.
Key Takeaways
- MP0730 becomes Molecular Partners’ lead CD70-targeting Radio-DARPin candidate and its third targeted alpha radiotherapy program.
- Mouse data presented on October 1 showed a biodistribution profile the company described as favorable, including uptake relative to kidney, liver and blood.
- Human development remains planned: the release refers to both mid-2027 and the second half of 2027 for the expected start.
Table of Contents
- MP0730 nomination follows preclinical distribution data
- CD70 provides the biological rationale
- A third program alongside the clinical-stage lead
- Conclusion
MP0730 nomination follows preclinical distribution data
The selection advances Molecular Partners’ effort to use DARPin miniproteins to deliver radioactive payloads to tumors. The company presented the supporting MP0730 data at the Discovery on Target – Radioligand Therapies conference in Boston on October 1, 2026.
According to Molecular Partners, the candidate demonstrated strong, sustained uptake in tumors compared with healthy tissues in mice. Those findings supported its selection, but they are preclinical results rather than evidence of safety or effectiveness in patients.
The development schedule is not stated consistently within the release. Its introductory highlights say the first-in-human program is expected to begin in the second half of 2027, while the main announcement says mid-2027.
CD70 provides the biological rationale
Molecular Partners describes CD70 as a clinically validated target through CAR-T cell therapies. The antigen is overexpressed in clear cell renal cell carcinoma, a form of kidney cancer, and other cancers. The company says its expression persists in metastases while remaining limited in healthy tissues.
That expression pattern underpins the company’s rationale for targeting CD70 with alpha radiation. Molecular Partners says clear cell renal cell carcinoma has robust DNA repair mechanisms and is inherently resistant to conventional cytotoxic therapies. Alpha radiation induces difficult-to-repair double-strand DNA breaks, offering a potential treatment approach rather than an established benefit for MP0730.
A third program alongside the clinical-stage lead
Molecular Partners designs its Radio-DARPins as vectors that can accommodate different isotopes. It says half-life extension and surface engineering are intended to address kidney accumulation and inadequate tumor uptake, two limitations of radioligand therapy.
Its lead medicine, MP0712, targets DLL3 and carries lead-212. That candidate is advancing in a US multicenter Phase 1/2a study involving patients with small cell lung cancer and other neuroendocrine cancers.
Conclusion
MP0730 adds a CD70-directed candidate to Molecular Partners’ radiotherapy pipeline. Its selection rests on mouse data, with the planned 2027 first-in-human program still ahead.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
